Recombinant zoster vaccine
Phase 3Vaccine
Recombinant zoster vaccine is one of 109 biologic programs targeting Rheumatic Disease. It is currently in Phase 3.
5
Indications
11
Total Trials
7
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
138 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Vumerity
BiogenPhase 3
Clemastine Fumarate
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Recombinant zoster vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Frexalimab
SanofiPhase 3
Tolebrutinib
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Herpes Zoster5 trials
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
Active, not recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 3·NCT06447779·25,000 enrolled
Show 2 more trials
A Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
Active, not recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 3·NCT07293065·12,000 enrolled
Multiple Sclerosis1 trial
Immunogenicity1 trial
2 more indications
Solid Organ Transplant Recipients1 trial
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
Enrolling by invitation·—·Phase 4·NCT06162494·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Recombinant zoster vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details